Chimeric antigen receptor <i>T</i>‐cell therapy combined with autologous stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large <i>B</i>‐cell lymphoma patients: A single‐center, retrospective, cohort study

Tao Wang(Second Military Medical University), Jianmin Yang(Canadian Food Inspection Agency), Gusheng Tang(Second Military Medical University), Mingyu Ye, Dongge Feng(Shanghai Huali Microelectronics (China)), Li Chen(Second Military Medical University), Aiping Zhang(Yangzhou University), Lili Xu(Shandong Academy of Agricultural Sciences), Xuejun Yu(Qilu Hospital of Shandong University), Lei Gao(Zhejiang Chinese Medical University), Weijia Fu(Second Military Medical University), Yang Wang(Second Military Medical University), Jiechen Yu(Second Military Medical University), Jie Chen(Guangdong Medical College), Wenqin Yue(Second Military Medical University)
Hematological Oncology
February 10, 2022
10.1002/hon.2975
Cited by 20

Related Papers

Recent advances in CAR-T cell engineering
|Journal of Hematology & Oncology|2020|403
Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance
|International Journal of Biological Sciences|2022|350
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
|The Lancet Haematology|2019|248
The 2.5 Å Crystal Structure of the SIRT1 Catalytic Domain Bound to Nicotinamide Adenine Dinucleotide (NAD<sup>+</sup>) and an Indole (EX527 Analogue) Reveals a Novel Mechanism of Histone Deacetylase Inhibition
|Journal of Medicinal Chemistry|2013|218